A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program-AIM-HY INFORM trial


Mukhtar, Omar, Cheriyan, Joseph, Cockcroft, John R, Collier, David, Coulson, James M, Dasgupta, Indranil, Faconti, Luca, Glover, Mark, Heagerty, Anthony M, Khong, Teck K et al (show 13 more authors) (2018) A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program-AIM-HY INFORM trial. AMERICAN HEART JOURNAL, 204. pp. 102-108.

Access the full-text of this item by clicking on the Open Access link.

Abstract

<h4>Background</h4>Ethnicity, along with a variety of genetic and environmental factors, is thought to influence the efficacy of antihypertensive therapies. Current UK guidelines use a "black versus white" approach; in doing so, they ignore the United Kingdom's largest ethnic minority: Asians from South Asia.<h4>Study design</h4>The primary purpose of the AIM-HY INFORM trial is to identify potential differences in response to antihypertensive drugs used as mono- or dual therapy on the basis of self-defined ethnicity. A multicenter, prospective, open-label, randomized study with 2 parallel, independent trial arms (mono- and dual therapy), AIM-HY INFORM plans to enroll a total of 1,320 patients from across the United Kingdom. Those receiving monotherapy (n = 660) will enter a 3-treatment (amlodipine 10 mg od; lisinopril 20 mg od; chlorthalidone 25 mg od), 3-period crossover, lasting 24 weeks, whereas those receiving dual therapy (n = 660) will enter a 4-treatment (amlodipine 5 mg od and lisinopril 20 mg od; amlodipine 5 mg od and chlorthalidone 25 mg od; lisinopril 20 mg od and chlorthalidone 25 mg od; amiloride 10 mg od and chlorthalidone 25 mg od), 4-period crossover, lasting 32 weeks. Equal numbers of 3 ethnic groups (white, black/black British, and Asian/Asian British) will ultimately be recruited to each of the trial arms (ie, 220 participants per ethnic group per arm). Seated, automated, unattended, office, systolic blood pressure measured 8 weeks after each treatment period begins will serve as the primary outcome measure.<h4>Conclusion</h4>AIM-HY INFORM is a prospective, open-label, randomized trial which aims to evaluate first- and second-line antihypertensive therapies for multiethnic populations.

Item Type: Article
Uncontrolled Keywords: Humans, Hypertension, Chlorthalidone, Amlodipine, Lisinopril, Antihypertensive Agents, Drug Therapy, Combination, Drug Administration Schedule, Prospective Studies, Cross-Over Studies, Adolescent, Adult, Aged, Middle Aged, Hemodynamics, Young Adult, United Kingdom, Asian People, White People, Black People
Depositing User: Symplectic Admin
Date Deposited: 13 May 2019 07:59
Last Modified: 15 Feb 2023 17:26
DOI: 10.1016/j.ahj.2018.05.006
Open Access URL: https://doi.org/10.1016/j.ahj.2018.05.006
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3040970
Dimensions
Altmetric
CORE (COnnecting REpositories)